Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy
Abstract
No abstract available
Elizabeth Bernardo : Connect in order to contact the contributor
https://www.hal.inserm.fr/inserm-03388040
Submitted on : Wednesday, October 20, 2021-10:50:46 AM
Last modification on : Friday, March 24, 2023-2:53:23 PM
Long-term archiving on: Friday, January 21, 2022-7:28:28 PM